Galectin Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -12 | 12 | |
EBITDA | -3,046 | -3,520 | -6,364 |
EBIT | -3,058 | -3,561 | |
Net Income | -5,046 | -5,500 | -8,184 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -3,866 | -6,042 | -3,542 |
Cash | 14,111 | 17,720 | 11,525 |
Basic Shares | 65,782 | 63,903 | 64,205 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -37 | -33 | -32 | |
EBITDA | -23,454 | -41,470 | -38,241 | -37,711 |
EBIT | -23,507 | -41,507 | -38,274 | -37,743 |
Net Income | -30,836 | -47,047 | -41,066 | -38,776 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -23,875 | -41,767 | -32,965 | -31,056 |
Cash | 17,720 | 15,120 | 25,660 | 18,592 |
Basic Shares | 63,903 | 62,309 | 60,159 | 59,391 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.14 |
2026-03-31 | -$0.08 |
2025-12-31 | -$0.08 |
2025-09-30 | -$0.13 |